
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing iodoquinol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing iodoquinol is listed. The only finished iodoquinol products in the directory are unapproved creams that also contain hydrocortisone acetate. None of the listed products containing iodoquinol is in suspension form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Iodoquinol is an anti-infective used by mouth against intestinal amoebae and on the skin that a pharmacy may compound when a prescriber orders it.
Iodoquinol is an anti-infective medicine that fights infections caused by amoebae. Taken by mouth, it acts as a luminal amebicide, clearing amebae inside the bowel (StatPearls); the CDC names paromomycin or iodoquinol as drugs of choice for amebiasis without symptoms and as follow-up after metronidazole or tinidazole. openFDA NDC lists no oral iodoquinol product; current listings are two topical creams and bulk powder, and DailyMed has no oral label. On the skin, iodoquinol has antifungal and antibacterial properties. Current products are creams that combine it with hydrocortisone acetate, such as Vytone cream, filed as unapproved drug other with indications, rated by the FDA DESI efficacy review as lacking full evidence, for eczema and other inflamed skin conditions. Drugs@FDA lists no application naming iodoquinol. A prescriber might order iodoquinol compounded in a form or combination that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Iodoquinol products carry no boxed warning. Do not use them if you are allergic to any ingredient. A Drugs.com monograph adds that oral iodoquinol should not be used with liver disease or a clioquinol or hydroxyquinoline allergy; tell your prescriber about thyroid disease, nerve problems or optic neuritis. Report vision changes, eye pain, numb or burning hands or feet, or neck swelling. Skin products are for external use only: keep them away from the eyes, lips and mucous membranes, and not on infants or under diapers or dressings. They can stain skin, hair and fabric. Iodoquinol absorbed through the skin can interfere with thyroid function tests, so such tests should wait at least one month after stopping, and it can cause a false positive phenylketonuria (PKU) diaper test. The cream label lists pregnancy category C and advises caution when nursing; no LactMed record was found. Talk to your prescriber or pharmacist about side effects.
Iodoquinol is a luminal amebicide; the CDC treatment page lists it (or paromomycin) to follow metronidazole or tinidazole, and as a drug of choice for asymptomatic infection. The Drugs.com monograph also lists Dientamoeba fragilis, Balantidium coli and Blastocystis infection among uses; these come from a discontinued product's monograph, not a current label. Topically, iodoquinol has antifungal and antibacterial activity and is combined with hydrocortisone acetate for its anti-inflammatory and antipruritic effect. The cream label notes that iodoquinol may be absorbed through the skin and interfere with thyroid function tests, so testing should wait at least one month after stopping, and that the ferric chloride PKU test may read falsely positive. Absorption of the corticosteroid rises with inflamed skin, large areas and occlusion; children absorb proportionally more. Labeled products: hydrocortisone acetate and iodoquinol creams (Vytone, Eckson Labs; a KMM Pharmaceuticals cream that also contains aloe), both unapproved drug other; pediatric safety under 12 years is not established. Dosing is per prescriber. Monitor for irritation, overgrowth of non-susceptible organisms with prolonged use and, with oral therapy, visual and neurologic symptoms. Iodoquinol is not a controlled substance.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally